Skip to content

Released Nov 12, 2014, before the open

10-Q filed Nov 12, 2014, 43 days after period end · 0001104659-14-079407

Q3 2014 · 10-Q
Revenue—
Net Income-$6.60MN/M vs Q3 2013N/M vs Q2 2014
EPS Diluted-$0.32N/M vs Q3 2013N/M vs Q2 2014
Operating Income-$5,984,000N/M
Operating Cash Flowderived-$5,521,000N/M
Free Cash Flowderived-$5,708,000—

What the release said

No earnings release is on file for this quarter. Its figures came with the 10-Q.

Same quarter

MetricQ3 2014Q3 2013Q3 2012
Revenue—$209.00K$528.00K
Net Income-$6.60M-$6.07M-$4.11M
EPS Diluted-$0.32-$4.81-$3.51

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Fate Therapeutics Inc · CIK 1434316 · Engraved from SEC EDGAR